Comprehensive solid tumor panel clinical report

Explore this clinical report investigating three genes, BRCA1, MYC and TP53 in a high grade serous ovarian tumor to investigate the sensitivity to PARP and VEGF inhibitors as possible therapeutic options. Examine the overall findings, and discover how this study was made possible with the TruSight^™ Oncology 5000 next-generation sequencing assay from Velsera.